NKGen Biotech, Inc. Common Stock
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease… Read more
NKGen Biotech, Inc. Common Stock (NKGN) - Net Assets
Latest net assets as of December 2025: $-50.33 Million USD
Based on the latest financial reports, NKGen Biotech, Inc. Common Stock (NKGN) has net assets worth $-50.33 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.84 Million) and total liabilities ($66.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-50.33 Million |
| % of Total Assets | -317.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NKGen Biotech, Inc. Common Stock - Net Assets Trend (2021–2023)
This chart illustrates how NKGen Biotech, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NKGen Biotech, Inc. Common Stock (2021–2023)
The table below shows the annual net assets of NKGen Biotech, Inc. Common Stock from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-58.69 Million | -3855.15% |
| 2022-12-31 | $1.56 Million | +104.11% |
| 2021-12-31 | $-38.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NKGen Biotech, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10970800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Components | $103.44 Million | % |
| Total Equity | $-58.69 Million | 100.00% |
NKGen Biotech, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of NKGen Biotech, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CT AUTOMOTIVE GROUP -005
F:X7X
|
$7.84 Million |
|
Boldt S.A
BA:BOLT
|
$7.84 Million |
|
EPB Group Berhad
KLSE:0317
|
$7.84 Million |
|
Repower Asia Indonesia PT
JK:REAL
|
$7.84 Million |
|
GUANGDONG KANG.CO.LTD YC1
F:E9Q
|
$7.83 Million |
|
Odonate Therapeutics
PINK:ODTC
|
$7.83 Million |
|
Keystone Reit Ltd
TA:KSTN
|
$7.83 Million |
|
Nico Resources Ltd
AU:NC1
|
$7.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NKGen Biotech, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,563,000 to -58,693,000, a change of -60,256,000 (-3855.2%).
- Net loss of 82,954,000 reduced equity.
- New share issuances of 1,668,000 increased equity.
- Other factors increased equity by 21,030,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-82.95 Million | -141.34% |
| Share Issuances | $1.67 Million | +2.84% |
| Other Changes | $21.03 Million | +35.83% |
| Total Change | $- | -3855.15% |
Book Value vs Market Value Analysis
This analysis compares NKGen Biotech, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-1.77 | $0.16 | x |
| 2022-12-31 | $0.07 | $0.16 | x |
| 2023-12-31 | $-3.80 | $0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NKGen Biotech, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-570.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -5461.27% | 0.02x | 0.00x | $-19.46 Million |
| 2022 | -1711.71% | -34745.45% | 0.00x | 10.45x | $-26.91 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-77.08 Million |
Industry Comparison
This section compares NKGen Biotech, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NKGen Biotech, Inc. Common Stock (NKGN) | $-50.33 Million | 0.00% | N/A | $7.84 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |